Spark Therapeutics to Participate in AAO Annual Meeting

PHILADELPHIA, Oct. 10, 2016 (GLOBE NEWSWIRE) — Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company seeking to transform the lives of patients with debilitating genetic diseases by developing potential one-time, life-altering treatments, announced today that members of company management and a principal investigator will participate in the following American Association of Ophthalmology (AAO) Annual Meeting events between Oct. 13 and Oct. 18:

2016 Ophthalmology Innovation Summit, or OIS@AAO, at the Hyatt Regency Chicago

  • Jeffrey D. Marrazzo, chief executive officer, will participate in the Gene Therapy Breakfast Break-Out Panel discussion on Thursday, Oct. 13, at 7:30 a.m. (CDT)

Retina Days Subspecialty Meeting, at the McCormick Center in Chicago

  • Albert M. Maguire, M.D., professor of ophthalmology at the Perelman School of Medicine of the University of Pennsylvania, will talk about “Gene Therapy for Leber Amaurosis Type 2 – Clinical Trials Results,” including data from the pivotal Phase 3 trial of voretigene neparvovec on Friday, Oct. 14, at 12:13 p.m. (CDT)

Additionally, the company will have a booth presence in the McCormick Center exhibit hall throughout the AAO meeting. Visit us at Booth 1980.

About Spark Therapeutics
Spark Therapeutics, a fully integrated gene therapy company, is seeking to transform the lives of patients with debilitating genetic diseases by developing potential one-time, life-altering treatments. Spark Therapeutics’ validated gene therapy platform is being applied to a range of clinical and preclinical programs addressing serious genetic diseases, including inherited retinal diseases, liver-associated diseases, such as hemophilia, and neurodegenerative diseases. Spark Therapeutics’ validated platform has successfully delivered proof-of-concept data with investigational gene therapies in the eye and liver. Spark Therapeutics’ most advanced product candidate, voretigene neparvovec (formerly referred to as SPK-RPE65), which has received both breakthrough therapy and orphan product designations, has reported top-line results from a pivotal Phase 3 clinical trial for the potential treatment of a rare blinding condition. Spark Therapeutics’ hemophilia franchise has two lead assets: SPK-9001 in a Phase 1/2 trial for hemophilia B and SPK-8011, a preclinical candidate for hemophilia A.  To learn more, please visit www.sparktx.com.

CONTACT: Spark Therapeutics Corporate Contacts 	
Stephen W. Webster, Chief Financial Officer 
Daniel Faga, Chief Business Officer		
(855) SPARKTX (1-855-772-7589)		

Media Contact
Dan Quinn
Ten Bridge Communications
(781) 475-7974
dan@tenbridgecommunications.com

NPHC Disclosure: We hold not shares and will not be receiving any shares. This means that as we release new information about a particular client company either on our site or otherwise authored by us, you can be confident we don’t own shares, will not be buying shares and will not be selling shares. StockGuru makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. We expect to be compensated up to five thousand seven hundred dollars for coverage, assuming three months coverage. StockGuru – McKinney, Texas 75070 – (469) 358-5200.

Logo Header Menu